SELLAS Life Sciences announced positive topline results from its Phase 3 REGAL trial for its AML cancer vaccine, GPS, meeting its primary endpoint with a significant reduction in death risk. This is a major positive catalyst for the company, paving the way for potential accelerated FDA approval and commercialization.
SELLAS Life Sciences reported highly positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML). The trial met its primary endpoint, showing a statistically significant 41% reduction in the risk of death, with median overall survival significantly extended. This is a critical milestone for SELLAS, as successful Phase 3 results are essential for regulatory approval. The company's plan to engage with the FDA for accelerated approval and prepare a Biologics License Application (BLA) indicates a clear path towards potential commercialization. This news is a strong positive catalyst for SLS stock in the short term, as it de-risks their primary asset and opens up a significant market opportunity in AML treatment. Long-term implications depend on successful FDA approval and market adoption, but the initial data is very promising.